EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment

Sergio Rodriguez-Rodriguez iD, Nihar Desai iD, Carol Chen, Kareem Jamani, Catherine Sohier-Poirier, Christopher Lemieux, Jennifer White, Mohamed Elemary iD, Michael Kennah, Tommy Alfaro Moya, Eshrak Al-Shaibani, Igor Novitzky-Basso und 7 weitere

British Journal of Haematology · 2025-11 · 207 (5) · 1874-1882

DOI: 10.1111/bjh.70146 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 14.09.2025. Verfasst von Sergio Rodriguez-Rodriguez und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, O…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Pyrazoles, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steroid‐refractory acute graft‐versus‐host disease (SR‐aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR‐aGvHD, failure predictors are poorly defined. We assessed 78 patients from six Canadian centres who received RUX for SR‐aGvHD. Failure‐free survival (FFS) was the primary end‐point. Endothelial activation and stress index (EASIX) scores were calculated at defined time points, dichotomized using recursive partitioning. A risk score for RUX failure was developed based on key variables. At RUX initiation, 76% of patients had grade 3–4 aGvHD. The best overall response rate was 75%; 58% experienced RUX failure, while the 6‐month FFS was 25.7%. EASIX gradually increased over time even after RUX ( p < 0.001). Patients with high EASIX at RUX ≥1.11 had a lower FFS at 6 months (17%) than the patients with low EASIX (54%) (hazard ratio [HR] 2.75 [95%CI 1.23–6.15], p = 0.014). A three‐factor RUX failure risk score—gut aGvHD, grade 4 aGvHD and high EASIX at RUX start—stratified patients by 6‐month FFS rates: 85.7%, 28.0% and 11.0% for score 0 ( n = 28), 1 ( n = 25) and ≥2 ( n = 34) (HR 2.25[1.42–3.55], p < 0.001). High EASIX can predict the risk of RUX failure in addition to gut aGvHD and grade 4 aGvHD. We propose to add other therapeutic interventions to RUX therapy pre‐emptively to high EASIX patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseasePyrazolesHematopoietic Stem Cell TransplantationHumansNitrilesPyrimidinesFemaleMaleMiddle AgedAdultBiomarkersAcute DiseaseAgedTreatment FailureSteroidsYoung AdultAdolescent

Stichwörter der Autor:innen

endothelial activation and stress index (EASIX)failure‐free survivalruxolitinib failuresteroid‐refractory acute graft versus host‐disease

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazolesBiomarkersSteroids

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Arthur Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
  • Centre hospitalier universitaire (CHU) de Québec, Université Laval, Québec, Québec, Canada.
  • Vancouver General Hospital, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Sergio Rodriguez-Rodriguez, Nihar Desai, Mohamed Elemary, Arjun Datt Law, Fotios V Michelis, Dennis Dong Hwan Kim

Zitieren

APA

Rodriguez-Rodriguez, S., Desai, N., Chen, C., Jamani, K., Sohier-Poirier, C., Lemieux, C., White, J., Elemary, M., Kennah, M., Alfaro Moya, T., Al-Shaibani, E., Novitzky-Basso, I., Pasic, I., Law, A. D., Michelis, F. V., Viswabandya, A., Kumar, R., Mattsson, J., & Kim, D. D. H. (2025). Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment. British Journal of Haematology, 207(5), 1874-1882. https://doi.org/10.1111/bjh.70146

Vancouver

Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, et al. Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment. British Journal of Haematology. 2025;207(5):1874-1882. doi:10.1111/bjh.70146

BibTeX
@article{RodriguezRodriguez2025,
  author = {Rodriguez-Rodriguez, Sergio and Desai, Nihar and Chen, Carol and Jamani, Kareem and Sohier-Poirier, Catherine and Lemieux, Christopher and White, Jennifer and Elemary, Mohamed and Kennah, Michael and Alfaro Moya, Tommy and Al-Shaibani, Eshrak and Novitzky-Basso, Igor and Pasic, Ivan and Law, Arjun Datt and Michelis, Fotios V and Viswabandya, Auro and Kumar, Rajat and Mattsson, Jonas and Kim, Dennis Dong Hwan},
  title = {Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {5},
  pages = {1874--1882},
  doi = {10.1111/bjh.70146}
}
Kostenlos starten →